How often do level III nodes bear melanoma metastases and does it affect patient outcomes?

Annals of Surgical Oncology

Volumn 20, Issue 6, 2013, Pages 2056-2064

  Nessim, Carolyn ^a   Law, Calvin ^a   McConnell, Yarrow ^b   Shachar, Sade ^a   McKinnon, Gregory ^b   Wright, Frances ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AXILLARY LYMPH NODE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS;

AXILLA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 84878247233     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2880-2     Document Type: Article

References (35)

1. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American joint committee on cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3622-34.
2. Bevilacqua RG, Coit DG, Rogatko A, Younes RN, Brennan MF. Axillary dissection in melanoma: prognostic variables in node-positive patients. Ann Surg. 1990; 212:125-31.
3. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-17.
4. Wright F, Spithoff K, Easson A, Murray C, Toye J, McCready D, Patrella T. Primary excision margins and sentinel lymph node biopsy in clinically node-negative melanoma of the trunk and extremities. Clin Oncol. 2011;23:572-8.
5. Plitas G, Aryian CE. Controversies in the management of regional nodes in melanoma. J NCCN. 2012;10:414-21.
6. Mack LA, McKinnon G. Controversies in the management of metastatic melanoma to regional lymphatic basins. J Surg Oncol. 2004;86:189-99.
7. Ariyan C, Brady MS, Gönen M, Busam K, Coit D. Positive non-sentinel node status predicts mortality in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16:186-90.
8. Ghaferi AA, Wong SL, Johnson TM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. Ann Surg Oncol. 2009;16:2978-84.
9. Easson AM, Rotstein LE, McCready DR. Lymph node assessment in melanoma. J Surg Oncol. 2009;99:176-85.
10. Karakousis CP. Therapeutic Node Dissections in Malignant Melanoma. Ann Surg Oncol. 1998;5:473-82.
11. Meyer T, Merkel S, Göhl J, Hohenberger W. Lymph node dissection for clinically evident lymph node metastases of malignant melanoma. EJSO. 2002; 28:424-30.
12. van Akkooi ACJ, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. EJSO. 2007;33:102-8.
13. Young SE, Martinez SR, Faries MB, Essner R, Wanek LA, Morton DL. Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer J. 2006;12:207-11.
14. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg. 2003;10:676-80.
15. Tominaga T, Takashima S, Danno M. Randomized clinical trial comparing level II and level III node dissection in addition to mastectomy for breast cancer. Br J Surg. 2004;91:38-43.
16. Larson D, Weinstein M, Goldberg I et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys. 1986;12:1575-82.
17. Pezner RD, Patterson MR, Hill LR et al. Arm Lymphedema in patients treated conservatively for breast cancer: relationship to patient age and axillary node dissection technique. Int J Radiat Oncol Biol Phys. 1986;12:2079-83.
18. Essner R. Surgical treatment of malignant melanoma. Surg Clin North Am. 2003;83:109-56.
19. NCCN (2012). Clinical practical guidelines in oncology-melanoma. 2011. http://www.nccn.org/profesion-als/physician-gls/PDF/melanoma.pdf. Accessed 15 March 2012.
20. Namm JP, Chang AE, Cimmino VM, Rees RS, Johnson TM, Sabel MS. Is a level III dissection necessary for a positive sentinel lymph node in melanoma? J Surg Oncol. 2012;105:225-8.
21. Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol. 2009;27:544-57.
22. Saha S, Farrar WB, Young DC, Ferrara JJ, Burak WE. Variation in axillary node dissection influences the degree of nodal involvement in breast cancer patients. J Surg Oncol. 2000;73:134-7.
23. Valsecchi ME, Silbermins D, deRosa N, Wong SL, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol. 2011;29:1479-87.
24. Ross MI, Gershenwald JE. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011;104:341-53.
25. Cadili A, McKinnon G, Wright F, Hanna W, Macintosh E, Abhari Z, Dabbs K. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. J Surg Oncol. 2010;101:191-4.
26. Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28:2452-59.
27. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg. 1989;124:1051-55.
28. Balch CM, Soong SJ, Murad TM, et al. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg. 1981;193:377-88.
29. Dutton-Regester K, Irwin D, Hunt H, et al. 2012 A high throughput panel for identifying clinically relevant mutation profiles in melanoma. Molecular Cancer Ther. doi: 10.1158/1535-7163.MCT-11-0676.
30. Lee B, Mukhi N, Liu D. Current management and novel agents for malignant melanoma. J Hematol Oncol. 2012;5:3-7.
31. Scolyer RA, Long GV, Thompson JF. Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Molecular Oncol. 2011;5:124-36.
32. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-16.
33. Gajewski TF. Molecular Profiling of melanoma and the evolution of patient-specific therapy. Sem Oncol. 2011;38:236-42.
34. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711.
35. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517.